PRIME
Zartauxfill PRIME is an advanced, S.C.E.D.I.S.™ patented, M.S.C.S. DVS cross-linked HA injectable gel (20 mg/ml), classified as a Class III medical device, designed for intradermal injection to correct fine lines, enhance delicate facial features, and address superficial scars or mild lipoatrophy depressions.
THE SCIENCE BEHIND
M.S.C.S.
PATENT
S.C.E.D.I.S.™
Introduction
Employing SCEDIS-MSCS technology to create ultrafine HA Neo-Spheres from monophasic, mono-densified cross-linked HA chains with enhanced bonds, PRIME's efficacy is supported by a pilot study on 16 females (mean age 40.5) demonstrating significant tear trough refinement (GAIS p=0.05; TTIS p=0.001 at one month) via microinjections (0.02–0.05 ml/site) with a 25G cannula, alongside a 20-patient evaluation confirming wrinkle reductions (p=0.063 via VISIA) and satisfaction (FACE-Q p=0.001 to 0.023), using statistical methods like Friedman ANOVA and Wilcoxon signed-rank tests, with no prolonged edema or adverse events.
​
Key Benefits
​​Containing 1ml of sterile cross-linked HA, PRIME ensures enduring volumization, smooth tissue integration, and safety, reducing superficial wrinkles while sculpting contours and augmenting lip volume for refreshed appearances, as evidenced by 43.2% TTIS improvement over one month.
Ideal for crow’s feet, lips vermillion border, philtra columns, tear trough deformities, moderate nasolabial wrinkles, perioral "barcode" lines, worry lines, periorbital lines, superficial scars, and mild facial lipoatrophy, PRIME enables subtle, natural enhancements in sensitive periorbital and perioral regions.
​
